Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07416513
Recruiting Not applicable

Digital Solutions for bEtter cAre

NCT07416513 · tracked via the Priya Life Science Spain tracker
Sponsor
European Institute of Oncology
Phase
Not applicable
Started
2025-05-14
Last updated
2026-02-18

Condition(s) studied

Cancer Diagnosis

Investigational drug(s) / intervention(s)

Patients, survivors, caregivers, family members and healthcare professionals

Patients, survivors, caregivers, family members and healthcare professionals: Focus group discussions (FGD) and completion of survey

Study summary

The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: HEALTHCARE PROFESSIONALS: * Healthcare professionals actually working in oncology and/or psychooncology; * Teachers of paediatric cancer patients. ADULT POPULATION: * Patients with a current or previous cancer diagnosis * Adequate language proficiency, * Able to provide informed consent; PAEDIATRIC POPULATION: * Older than 12 years of age; * Patients with a current or previous cancer diagnosis; * Adequate language proficiency; * Legal guardians of paediatric cancer patients able to provide informed consent. CAREGIVERS: * Caregivers and/or family members of cancer patients who lived or assist the loved ones with a current or previous cancer diagnosis in the cancer journey; * Adequate language proficiency; * Able to provide informed consent; * Caregivers and/or family members of paediatric cancer patients under 12 years of age. Exclusion Criteria: * Healthcare professionals with limited oncology patient contact; * Insufficient knowledge of the local language; * Severe cognitive impairment, and/or mental disorders that prohibited their participation in the study or inadequate verbal skills that may render them incapable of informed consent (as evaluated by the clinician); * Inability to understand the study materials (as evaluated by the clinician); * Physical or psychological impairment that prohibits their participation in focus groups (as evaluated by the clinician).

Primary outcome measure(s)

  • Number of unmet needs of patients, caregivers and Health Care Professionals (HCPs) — 15 months
    Number of unmet needs reported by patients, caregivers and Health Care Professionals (HCPs)

Trial sites (5)

FacilityCityRegionStatus
Centre François Baclesse Caen France Recruiting
Saarland University Homburg Germany Not Yet Recruiting
European Institute of Oncology Milan Italy Not Yet Recruiting
National Cancer Institute Vilnius Lithuania Not Yet Recruiting
Catalan Institute of Oncology Barcelona Spain Not Yet Recruiting

More European Institute of Oncology trials in Spain

Sentinel Node Vs Observation After Axillary Ultra-souND Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07416513 on ClinicalTrials.gov ↗ ← All trials in Spain